ASH Abstracts 2019
Oncopeptides to Highlight Data from Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019.
Documents
-
ANCHOR (OP-104) Updated Efficacy and Safety from a Phase 1 and 2 StudyPDF, 0.2 MB
-
Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multible Myeloma - HORIZON (OP-106)PDF, 0.2 MB
-
In Vitro and in Vivo Activity of Melflufen in AmyloidosisPDF, 0.1 MB
-
OP2011 A Phase 12 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) AmyPDF, 0.2 MB
-
The Burden of RelapsedRefractory Multiple Myeloma An Indirect Comparison of Health-Related Quality of LifePDF, 0.3 MB
-
Updated Progression-Free Survival (PFS) and Overall Survival (OS) from phase 2 study O-12-M1PDF, 0.3 MB